Sitemap Contact Privacy Statement Imprint

Anti-hormone Drug Metabolism and Pharmacodynamics

Dr. Thomas Mürdter

phone: ++49-711-8101 5974

Major Projects
  • Influence of pharmacogenetics on the metabolism of Selective Estrogen Receptor Modulators
  • Synthesis and analysis of phase I and II metabolites
  • Ex vivo models of human tumors
Selected References
  • Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, Sauer G, Aulitzky WE, van der Kuip H. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. Cancer Res. 2016 May 15;76(10):2868-75.
Major Networks and Collaborations
  • TAMENDOX: Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients
Extramural Funding
  • BMBF (Federal Ministry of Education and Research): Initiative Individualized Medicine: TAMENDOX
  • DFG (German Research Foundation): The role of agonistic metabolites in Tamoxifen resistance

Curriculum Vitae Thomas Mürdter, PhD

Affiliation
Principal Investigator at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart Germany
phone: ++49-711-8101 5974
fax: ++49-711-859295
email: thomas.muerdter@ikp-stuttgart.de
Education and Professional Career
1984-1987 Undergraduate studies in Chemistry at University of Stuttgart
1988 Industrial traineeship at PLIVA Ltd. Zagreb, Yugoslavia
1988-1991 Graduate studies in Chemistry with elective subject Biochemistry at University of Stuttgart
1991 Diploma Thesis at the Department of Chemical Microbiology at the Fraunhofer Institute for Interfacial Engineering and Biotechnology: Degradation of trichloroethylene by the alcaligenes denitrificans ssp xylosoxidans strain JE95
1991-1992 Research fellow at the Fraunhofer Institute for Interfacial Engineering and Biotechnology
1992-1994 Deputy head of the Department of Polymer and Environmental Analysis at the Institute of Polymeric Sciences, Stuttgart, Germany
1994-1997 PhD studies at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
1997 PhD in Chemistry. Thesis: Distribution, tumour selectivity, and bio-activation of doxorubicin in the isolated perfused human lung model.
Since 1997 Scientist at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Professional Memberships
Since 1998: Member of the DGTP (German Society of Toxicology and Pharmacology)